Activity ratios measure how efficiently a company performs day-to-day tasks, such us the collection of receivables and management of inventory.
Paying user area
Try for free
Abbott Laboratories pages available for free this week:
- Income Statement
- Analysis of Solvency Ratios
- Analysis of Geographic Areas
- Present Value of Free Cash Flow to Equity (FCFE)
- Return on Equity (ROE) since 2005
- Debt to Equity since 2005
- Total Asset Turnover since 2005
- Price to Earnings (P/E) since 2005
- Price to Operating Profit (P/OP) since 2005
- Aggregate Accruals
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Abbott Laboratories for $24.99.
This is a one-time payment. There is no automatic renewal.
We accept:
Long-term Activity Ratios (Summary)
Based on: 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31).
The analysis of the provided financial ratios over successive quarterly periods reveals distinct trends in asset utilization and equity efficiency.
- Net Fixed Asset Turnover
- The ratio demonstrates an initial strong upward trajectory from March 2020, starting at approximately 3.83 and peaking near 5.18 by the fourth quarter of 2022. This increase suggests improving efficiency in generating sales from fixed assets during that period. However, post-peak, the ratio exhibits a declining trend, falling to around 3.78 by mid-2025. This decline may indicate either a slowdown in sales growth relative to fixed asset investments or increasing fixed asset base without proportional revenue gains.
- Total Asset Turnover
- This ratio shows a generally positive trend from 0.48 in early 2020, rising steadily to a high of approximately 0.62 by late 2021. Following that, the ratio stabilizes with minor fluctuations, maintaining levels around 0.55 to 0.56 through 2024 before a slight decline toward 0.51 by mid-2025. The pattern suggests an initial improvement in utilizing total assets to generate revenue, followed by a plateau and a marginal decrease, highlighting potential challenges in sustaining asset efficiency.
- Equity Turnover
- Equity turnover exhibits growth from 1.06 in early 2020 to a peak near 1.26 during 2021, reflecting increased revenue generation relative to shareholders' equity. After reaching this peak, the ratio gradually declines, falling to about 0.85 by mid-2025. This downward trend may indicate reduced effectiveness in leveraging equity for sales growth or increased equity base not matched by sales expansion over time.
In summary, the period from 2020 through 2021 shows marked improvements in operational efficiency across all examined turnover metrics. However, from 2022 onward, each ratio signals a diminishing capacity to sustain the earlier gains, suggesting a need for strategic review to address potential inefficiencies in asset and equity utilization going forward.
Net Fixed Asset Turnover
Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Selected Financial Data (US$ in millions) | |||||||||||||||||||||||||||||
Net sales | |||||||||||||||||||||||||||||
Net property and equipment | |||||||||||||||||||||||||||||
Long-term Activity Ratio | |||||||||||||||||||||||||||||
Net fixed asset turnover1 | |||||||||||||||||||||||||||||
Benchmarks | |||||||||||||||||||||||||||||
Net Fixed Asset Turnover, Competitors2 | |||||||||||||||||||||||||||||
Elevance Health Inc. | |||||||||||||||||||||||||||||
Intuitive Surgical Inc. | |||||||||||||||||||||||||||||
Medtronic PLC | |||||||||||||||||||||||||||||
UnitedHealth Group Inc. |
Based on: 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31).
1 Q2 2025 Calculation
Net fixed asset turnover
= (Net salesQ2 2025
+ Net salesQ1 2025
+ Net salesQ4 2024
+ Net salesQ3 2024)
÷ Net property and equipment
= ( + + + )
÷ =
2 Click competitor name to see calculations.
The quarterly financial data demonstrates several notable trends in sales performance, asset utilization, and investment in property and equipment over the observed periods.
- Net Sales
- Net sales exhibited overall growth from March 2020 through March 2025, starting at approximately 7.7 billion USD and culminating near 10.4 billion USD by mid-2025. The sales figures fluctuated within quarters but showed a persistent upward trajectory. Slight declines are observed mid-periods (for example, a dip around mid-2022 and again in early 2023), but the general pattern reflects recovery and incremental increases by the later stages.
- Net Property and Equipment
- The net value of property and equipment consistently increased over the entire timeframe, rising from about 7.9 billion USD in early 2020 to roughly 11.4 billion USD by mid-2025. This indicates a continuous investment in fixed assets, with no significant periods of reduction, implying a strategic focus on expanding or upgrading physical assets.
- Net Fixed Asset Turnover Ratio
- The net fixed asset turnover ratio, available from the end of 2020 onwards, shows a declining trend. Initially, the ratio increased, peaking around the second and third quarters of 2021 at values above 5.0, suggesting efficient use of fixed assets to generate sales. From that peak, the ratio steadily decreased, falling to below 4.0 by mid-2025. This downward trend indicates that sales growth is not keeping pace with the growth in property and equipment. Consequently, asset utilization efficiency has lessened over time.
In summary, while the company has experienced robust growth in net sales accompanied by continuous investment in property and equipment, the efficiency in utilizing these assets to generate sales has declined in recent years. This could suggest the need to evaluate asset deployment strategies to enhance turnover or adapt capital expenditure plans to optimize returns.
Total Asset Turnover
Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Selected Financial Data (US$ in millions) | |||||||||||||||||||||||||||||
Net sales | |||||||||||||||||||||||||||||
Total assets | |||||||||||||||||||||||||||||
Long-term Activity Ratio | |||||||||||||||||||||||||||||
Total asset turnover1 | |||||||||||||||||||||||||||||
Benchmarks | |||||||||||||||||||||||||||||
Total Asset Turnover, Competitors2 | |||||||||||||||||||||||||||||
Elevance Health Inc. | |||||||||||||||||||||||||||||
Intuitive Surgical Inc. | |||||||||||||||||||||||||||||
Medtronic PLC | |||||||||||||||||||||||||||||
UnitedHealth Group Inc. |
Based on: 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31).
1 Q2 2025 Calculation
Total asset turnover
= (Net salesQ2 2025
+ Net salesQ1 2025
+ Net salesQ4 2024
+ Net salesQ3 2024)
÷ Total assets
= ( + + + )
÷ =
2 Click competitor name to see calculations.
The financial data reveals several trends concerning net sales, total assets, and total asset turnover over multiple quarters.
- Net Sales
- Net sales demonstrate a fluctuating pattern with periodic increases and decreases. Starting at 7,726 million US dollars in Q1 2020, sales dipped slightly in the second quarter before rising notably to a peak of 11,468 million in Q4 2021. Following this peak, sales experienced a gradual decline reaching a low of 9,747 million by Q1 2023. Subsequently, there was a mild recovery with sales climbing back above 10,000 million through the remaining quarters, reaching 11,142 million by Q2 2025. This indicates a generally stable but somewhat volatile revenue stream with cycles of growth and contraction.
- Total Assets
- Total assets show an overall increasing trend with some volatility. Assets begin at 66,777 million US dollars in Q1 2020 and rise steadily to a high of about 75,196 million by Q4 2021. A period of relative stagnation and slight decline follows through 2022 and early 2023, with assets fluctuating between approximately 72,000 and 74,000 million. From Q1 2024 onwards, total assets exhibit more pronounced growth, reaching approximately 83,999 million by Q4 2025. This growth suggests ongoing investment or accumulation of resources over the medium term.
- Total Asset Turnover
- The ratio of total asset turnover, which measures efficiency in generating sales from assets, presents an improvement at the beginning of the observable period. From a ratio of 0.48 in Q3 2020, it progressively climbs to a peak of 0.62 in Q4 2022. After this high point, the turnover ratio declines gradually to 0.51 by Q4 2025. This pattern implies a phase of increasing efficiency in asset utilization, followed by a reduction in the rate of turnover, suggesting that despite asset growth, sales are not increasing proportionately in the latter quarters.
- Overall Insights
- Overall, net sales and total assets both show long-term upward trends, although net sales display more cyclical behavior. The increase in total assets indicates expansion or capital accumulation, which is not consistently matched by proportional increases in sales, especially in more recent quarters as reflected by the declining asset turnover ratio. This could point to potential challenges in operational efficiency or the need for strategic adjustments to enhance the productivity of asset investments.
Equity Turnover
Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Selected Financial Data (US$ in millions) | |||||||||||||||||||||||||||||
Net sales | |||||||||||||||||||||||||||||
Total Abbott shareholders’ investment | |||||||||||||||||||||||||||||
Long-term Activity Ratio | |||||||||||||||||||||||||||||
Equity turnover1 | |||||||||||||||||||||||||||||
Benchmarks | |||||||||||||||||||||||||||||
Equity Turnover, Competitors2 | |||||||||||||||||||||||||||||
Elevance Health Inc. | |||||||||||||||||||||||||||||
Intuitive Surgical Inc. | |||||||||||||||||||||||||||||
Medtronic PLC | |||||||||||||||||||||||||||||
UnitedHealth Group Inc. |
Based on: 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31).
1 Q2 2025 Calculation
Equity turnover
= (Net salesQ2 2025
+ Net salesQ1 2025
+ Net salesQ4 2024
+ Net salesQ3 2024)
÷ Total Abbott shareholders’ investment
= ( + + + )
÷ =
2 Click competitor name to see calculations.
The analysis of the quarterly financial data reveals several notable trends in the key metrics over the period from March 2020 to June 2025.
- Net Sales
- The net sales figures exhibit some fluctuation with a general upward tendency over the long term. Initially, net sales dropped from $7,726 million in March 2020 to $7,328 million in June 2020, followed by a recovery and steady increase reaching a peak around December 2021 with $11,468 million. After that, the sales trend shows a slight decline through 2022, hitting a low of $9,747 million in March 2023. Subsequently, an upward recovery occurs, with net sales rising again to $11,142 million by June 2025. These fluctuations suggest some cyclical or market-related impacts influencing sales volumes within these periods.
- Total Abbott Shareholders’ Investment
- This metric displays a consistently upward trajectory throughout the examined period. Starting at $30,218 million in March 2020, the total shareholders’ investment steadily increases quarter over quarter, reaching a significant level of $50,565 million by June 2025. The growth is largely steady without major interruptions, indicating an ongoing accumulation of shareholder equity, possibly from retained earnings, capital contributions, or valuation changes, reflecting growing company value or reinvestment strategies.
- Equity Turnover Ratio
- The equity turnover ratio, available from September 2020 onwards, initially rises from 1.06 to a peak of 1.26 around mid-2021 and sustains this relatively high level through late 2021 and early 2022. Subsequently, there is a gradual decline in this ratio through the later periods, dropping to approximately 0.85 by June 2025. This downward trend in equity turnover indicates a decreasing efficiency in using shareholders' equity to generate sales over time, which may reflect changing operational dynamics or larger equity bases relative to sales.
In summary, net sales demonstrate cyclical patterns with a general positive slope, while total shareholders' investment shows consistent growth. The equity turnover ratio improvement early on suggests enhanced equity utilization efficiency initially, followed by a gradual decrease, highlighting a potential area for management focus on optimizing the use of equity capital relative to sales generation in future periods.